The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1501466
Case report: A rare case of a long-term survivor of glioblastoma who underwent two courses of hypofractionated radiotherapy as part of their care
Provisionally accepted- 1 Des Moines University, Des Moines, United States
- 2 Department of Radiation Oncology, Medical School, University of Minnesota, Minneapolis, Minnesota, United States
- 3 Masonic Cancer Center, Medical School, University of Minnesota, Minneapolis, Minnesota, United States
- 4 Department of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minnesota, Minnesota, United States
- 5 Department of Neurology, Medical School, University of Minnesota, Minneapolis, Minnesota, United States
Glioblastoma is a primary brain tumor that is managed by a multidisciplinary care team, including radiation oncologists, neuro-oncologists, neurosurgeons, neuropathologists and neuroradiologists. Radiotherapy is part of the standard treatment paradigm. Discussing a rare case report about a long-term survivor of glioblastoma who was treated with two hypofractionated courses of radiotherapy is important to share with providers who take care of these patients and researchers who study this disease.
Keywords: Glioblastoma, Long-Term survivor, Hypofractionated Radiotherapy, case report, reirradiation
Received: 27 Sep 2024; Accepted: 07 Jan 2025.
Copyright: © 2025 Mrvoljak, Mishra, Chen, Neil, Ehler, Terezakis and Sloan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lindsey Sloan, Department of Radiation Oncology, Medical School, University of Minnesota, Minneapolis, MN 55455, Minnesota, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.